Journal of Hematology Oncology Pharmacy

Featured Articles

Outcomes of Pharmacist-Provided Telehealth Services in an Ambulatory Oncology Clinic During the COVID-19 Pandemic

Colleen Bohnenkamp, PharmD, BCOP, BCPS, Grace A. Martin, PharmD, BCOP, Laure DuBois, PharmD, BCOP, Olivia Fahey, PharmD, BCOP, Jade Hefler, PharmD

Successful Treatment of Nivolumab plus Ipilimumab–Mediated Pure Red-Cell Aplasia and Diabetes with Cyclosporine

Parikshit Padhi, MD, MBBS, Traci M. White, PharmD, PhC, BCGP, Neslihan Cetin, MD

Tolerance of Oral Targeted Therapies in Patients with Metastatic Renal-Cell Carcinoma and Renal Impairment

Jessica McKernan, PharmD, BCOP, Laura Schmidt, PharmD, BCOP, Melissa Rhoades, PharmD, BCOP

Recent Targeted Therapies Approved for the Treatment of Patients with Urothelial Carcinoma

Bojana Stevich-Heemer, MS, PharmD, MEd, BCOP

Urine Alkalinization and Methotrexate Clearance: Are These Key to Safe Administration of High-Dose Methotrexate?

Joseph Bubalo, PharmD, BCPS, BCOP

Efficacy of an Enteral Urine Alkalinization Strategy During Intravenous Sodium Bicarbonate Shortage in Patients with Cancer Receiving High-Dose Methotrexate

Christopher Sinoimeri, PharmD, Matthew Lei, PharmD, BCOP, Stephanie Monaco, PharmD, BCOP, Uvette Lou, PharmD, BCOP

From the Literature

Daily Aspirin Does Not Lower Colorectal Cancer Risk When Started After Age 70

Adjuvant Nivolumab Therapy Prolongs Disease-Free Survival in Patients with Esophageal Cancer

New Data Reveal Mismatched Need and Supply of Oncology Physicians and Pharmacists in America

Low-Dose Capecitabine Maintenance Therapy Improves Survival in Patients with Triple-Negative Breast Cancer

Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA

Enfortumab Vedotin Superior to Chemotherapy in Urothelial Cancer

Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA

Oral Azacitidine Prolongs Survival in Patients with Acute Myeloid Leukemia

Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA

FDA Updates

Tivdak First Antibody–Drug Conjugate FDA Approved for Recurrent or Metastatic Cervical Cancer

Exkivity Novel Oral Targeted Therapy Approved for Metastatic NSCLC with EGFR Exon 20 Insertion Mutations

Welireg FDA Approved for 3 Tumor Types Associated with von Hippel-Lindau Disease

Rezurock Novel Oral Therapy FDA Approved for Chronic Graft-Versus-Host Disease

Jakafi a New Treatment Option for Chronic Graft-Versus-Host Disease

Cabometyx Receives FDA Approval for Differentiated Thyroid Cancer

Meeting Highlights

Atezolizumab, Vemurafenib, and Cobimetinib Triplet Therapy Improves PFS in BRAF-Positive Melanoma

Two Ways to Target Tumors with KRAS Mutations

Targeted Therapy with Olaparib Beneficial in Metastatic Prostate Cancer with Gene Mutations

Ceritinib Effective in Treating Brain Metastases in NSCLC

Paradigm Shift: PARP Inhibitors Should Be Offered to All Patients with Ovarian Cancer

Adding CDK4/6 Inhibitor to Endocrine Therapy Improves Survival in Advanced Breast Cancer: New Standard of Care

Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.